Skip to contentL
Lifecore Biomedical, Inc.
L
LFCRLifecore Biomedical, Inc. Q2 2023 · 10-Q
Revenue$21.86M$21.86M−14.6% vs Q2 2022 Net Income-$12.81M-$12.81MN/M vs Q2 2022 EPS Diluted-$0.43-$0.43N/M vs Q2 2022 Gross Profit$5,679,000−50.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lifecore Biomedical, Inc. · CIK 1005286 · Engraved from SEC EDGAR
Operating Cash Flowderived-$1,921,000N/M Free Cash Flowderived-$6,201,000N/M Margins · derivedGross margin26.0%−18.8 pt vs Q2 2022
Operating margin-24.5%−38.9 pt vs Q2 2022
Net margin-58.6%+91.7 pt vs Q2 2022
ended Nov 27, 2022 · filed Mar 16, 2023 · 109 d after period end